ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.9 CNY | +3.40% |
|
+6.76% | -15.60% |
| Sales 2023 * | 12.65B 1.75B 146B | Sales 2024 * | 13.27B 1.83B 153B | Capitalization | 9.4B 1.3B 108B |
|---|---|---|---|---|---|
| Net income 2023 * | 605M 83.66M 6.98B | Net income 2024 * | 648M 89.61M 7.47B | EV / Sales 2023 * | 1.09 x |
| Net Debt 2023 * | 4.42B 611M 50.93B | Net Debt 2024 * | 3.53B 487M 40.66B | EV / Sales 2024 * | 0.97 x |
| P/E ratio 2023 * |
15.6
x | P/E ratio 2024 * |
14.4
x | Employees | 8,325 |
| Yield 2023 * |
0.79% | Yield 2024 * |
0.92% | Free-Float | 53.86% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.40% | ||
| 1 week | +6.76% | ||
| Current month | +2.73% | ||
| 1 month | +3.00% | ||
| 3 months | -10.43% | ||
| 6 months | -25.61% | ||
| Current year | -15.60% |
1 week
7.33
7.90
1 month
7.277.99
Current year
6.439.84
1 year
6.4313.54
3 years
6.4317.90
5 years
6.4321.97
10 years
6.4327.93
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Qing Yang
CEO | Chief Executive Officer | - | 31/23/31 |
Jia Qiu Du
CHM | Chairman | 50 | 13/19/13 |
Wei Hong Xiao
PSD | President | 56 | 11/23/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shun Bing Yu
CHM | Chairman | 61 | - |
Jia Yi Zhao
BRD | Director/Board Member | 64 | 13/19/13 |
Li Rong Yang
BRD | Director/Board Member | 62 | 13/19/13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.57% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 7.9 | +3.40% | 13 256 400 |
| 26/24/26 | 7.64 | +1.33% | 8,808,271 |
| 25/24/25 | 7.54 | +2.03% | 9,270,063 |
| 24/24/24 | 7.39 | -0.54% | 6,512,748 |
| 23/24/23 | 7.43 | -0.13% | 5,983,600 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
Zhejiang Hisun Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of specialty bulk pharmaceutical chemicals and preparation products. The Company's bulk pharmaceutical chemicals mainly include antineoplastic drugs, cardiovascular drugs, anti-infection drugs, endocrine control drugs, anthelmintic, as well as animal remedies, among others. The Company is also engaged in the sales of drugs manufactured by other companies. The Company distributes its products in domestic markets and to overseas markets.
Sector
Pharmaceuticals
Calendar
30/04/2024
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
7.9
CNY
Average target price
7.4
CNY
Spread / Average Target
-6.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.60% | 1.25B | |
| +26.25% | 661B | |
| +26.74% | 566B | |
| -6.77% | 352B | |
| +19.48% | 332B | |
| +3.44% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.40% | 145B |
- Stock Market
- Equities
- 600267 Stock
